期刊文献+

肿瘤特异性启动子驱动的RNA干扰与肿瘤基因靶向治疗 被引量:1

RNA interference driven by tumor-specific promoters and targeted therapy of tumor
原文传递
导出
摘要 应用肿瘤特异性启动子如甲胎蛋白启动子、人端粒酶逆转录酶启动子、存活素启动子等,驱动RNA干扰(RNAi)在肿瘤组织中发挥靶向治疗效应。该方法把肿瘤启动子的特异性和RNAi的高效性有机结合起来,可以实现对肿瘤组织的特异、高效杀伤作用。肿瘤特异性启动子驱动的RNAi在肿瘤基因靶向治疗中发挥重要作用。 RNA interference driven by tumor specific promoters has targeted therapeutic effect only in tumor tissue, it is a new method in tumor gene therapy, such as alpha-fetoprotein promoter, human telomerase re- verse transcriptase promoter, survivin promoter and etc. This method binds specificity of tumor promoter and high effects of RNAi, and can realize specific and highly killing effects in tumor tissue. RNAi driven by tumor specific promoters plays an important role in tumor oncogene targeted therapy.
出处 《国际肿瘤学杂志》 CAS 2009年第12期894-896,共3页 Journal of International Oncology
关键词 肿瘤 启动子 基因 RNA干扰 Neoplasms Promoter regions Genes RNA interference
  • 相关文献

参考文献21

  • 1Dykxhoom DM, Lieberman J. The silent revolution:RNA interference as basic biology, research tool, and therapeutic. Ann Rev Med, 2005, 56:401-423.
  • 2Martinelli R, De Simone V. Short and highly efficient synthetic promotets for melanoma-specific gene expression. FEBS Lett, 2005, 579 (1) :153-156.
  • 3Kuo MF, Wang HS, Kuo QT, et al. High expression of stathmin protein predicts a fulminant course in medulloblastoma. J Neurosurg Pediatr, 2009, 4( 1 ) :74-80.
  • 4Zhang HZ, Wang Y, Gao P, et al. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biol Ther, 2006, 5 ( 11 ) : 1457-1461.
  • 5Dong K, Wang R, Wang X, et al. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat, 2009, 113(3) :443-456.
  • 6Wang R, Lin F, Wang X, et al. The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression. Cancer Biol Ther, 2007, 6 (8) : 1295-1301.
  • 7Cukusie A, Skrobot Vidacek N, Sopta M, et al. Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res, 2008, 122 (3-4) :263-272.
  • 8Uiopoulos D, Satra M, Drakaki A, et al. Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int J Oncol, 2009, 34 (2) :391-399.
  • 9Carvalho L, Lipay M, Belfort F, et al. Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg, 2006, 59(9) :961-968.
  • 10Burendahl S, Treuter E, Nilsson L Molecular dynamics simulations of human LRH- 1 : the impact of ligand binding in a constitutively active nuclear receptor. Biochemistry, 2008, 47 ( 18 ) :5205-5215.

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部